BRAF Overexpression

CI-VAR-00003228Explore in graph →CIViC 3735

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Melanoma1
BRAF Overexpression	Dabrafenib + PLX4720 + Trametinib + VemurafenibCombination	Predictive	D	Supports Resistance	2	submitted	EID10156 Association between BRAF-V600E allele amplification and resistance to MEK and BRAF inhibitors was demonstrated in melanoma cell lines and PDX models. Trametinib resistant cells lines distinctly displa… (full text at CIViC) PMID 24055054 · Villanueva et al., 2013 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.